Related Experiment Videos
Group B streptococci during pregnancy and infancy.
1Department of Pediatrics, University Hospital Freiburg, Freiburg, Germany. berner@kikli.ukl.uni-freiburg.de
Current Opinion in Infectious Diseases
|May 17, 2002
Summary
Group B Streptococcus (Streptococcus agalactiae) infections remain a perinatal concern. New vaccines and understanding of immune responses offer future prevention strategies despite antibiotic resistance challenges.
Area of Science:
- Obstetrics and Gynecology
- Neonatal Medicine
- Infectious Diseases
Background:
- Group B Streptococcus (GBS) remains a significant perinatal pathogen, despite reduced neonatal invasive infections due to maternal antimicrobial prophylaxis.
- Current prophylaxis strategies fail to prevent preterm delivery or late-onset GBS sepsis.
- Increasing global antibiotic resistance complicates GBS management.
Purpose of the Study:
- To review advances in GBS prevention and treatment strategies.
- To highlight the potential of new conjugate vaccines and virulence factor research.
- To discuss the immune response pathways relevant to GBS infection.
Main Methods:
- Review of recent scientific literature on Group B Streptococcus.
- Analysis of developments in conjugate vaccine technology.
- Examination of research into GBS virulence factors and host immune responses.
Main Results:
- Significant progress has been made in developing GBS conjugate vaccines.
- Research has identified key virulence factors and immune pathways involved in GBS pathogenesis.
- Some novel strategies show promise for future clinical application.
Conclusions:
- Despite prophylaxis successes, GBS remains a critical perinatal issue.
- Advances in vaccine development and understanding GBS immunity offer hope for improved prevention.
- Future clinical practice may incorporate new GBS interventions.